Alan S Wayne1, Christian M Capitini, Crystal L Mackall. 1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room #1-3750, 9000 Rockville Pike, MSC 1104, Bethesda, MD 20892-1104, USA. waynea@mail.nih.gov
Abstract
PURPOSE OF REVIEW: Most children with cancer can be cured with combination regimens of chemotherapy, radiation, surgery, or all. However, standard therapies are toxic to normal tissues, cancer cells commonly develop resistance to chemotherapy, and relapsed malignancy is a leading cause of mortality in pediatrics. Elucidation of the principles of the normal immune response and tumor biology, coupled with technological developments, have led to important advances in the field of cancer immunotherapy. This review summarizes the biologic basis of cancer immunotherapy and highlights recent examples of progress in the application of novel humoral and cellular immunotherapies to children and adolescents with malignancy. RECENT FINDINGS: Clinical trials of immunotherapy for pediatric cancer have recently been initiated. To date, most immune-based therapies have been well tolerated and some have shown clinically significant activity against specific refractory high-risk malignancies. SUMMARY: Recent clinical trial results provide proof-of-principle that cancer immunotherapy has the capacity to overcome chemotherapy resistance without the usual toxicities associated with cytotoxic regimens. Immunotherapy holds promise in the treatment of children and adolescents with cancer and has the potential to improve both survival and quality of life.
PURPOSE OF REVIEW: Most children with cancer can be cured with combination regimens of chemotherapy, radiation, surgery, or all. However, standard therapies are toxic to normal tissues, cancer cells commonly develop resistance to chemotherapy, and relapsed malignancy is a leading cause of mortality in pediatrics. Elucidation of the principles of the normal immune response and tumor biology, coupled with technological developments, have led to important advances in the field of cancer immunotherapy. This review summarizes the biologic basis of cancer immunotherapy and highlights recent examples of progress in the application of novel humoral and cellular immunotherapies to children and adolescents with malignancy. RECENT FINDINGS: Clinical trials of immunotherapy for pediatric cancer have recently been initiated. To date, most immune-based therapies have been well tolerated and some have shown clinically significant activity against specific refractory high-risk malignancies. SUMMARY: Recent clinical trial results provide proof-of-principle that cancer immunotherapy has the capacity to overcome chemotherapy resistance without the usual toxicities associated with cytotoxic regimens. Immunotherapy holds promise in the treatment of children and adolescents with cancer and has the potential to improve both survival and quality of life.
Authors: A A Cardoso; J L Schultze; V A Boussiotis; G J Freeman; M J Seamon; S Laszlo; A Billet; S E Sallan; J G Gribben; L M Nadler Journal: Blood Date: 1996-07-01 Impact factor: 22.113
Authors: J R Passweg; P Tiberghien; J Y Cahn; M R Vowels; B M Camitta; R P Gale; R H Herzig; D Hoelzer; M M Horowitz; N Ifrah; J P Klein; D I Marks; N K Ramsay; P A Rowlings; D J Weisdorf; M J Zhang; A J Barrett Journal: Bone Marrow Transplant Date: 1998-01 Impact factor: 5.483
Authors: R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544
Authors: L Bowman; M Grossmann; D Rill; M Brown; W Y Zhong; B Alexander; T Leimig; E Coustan-Smith; D Campana; J Jenkins; D Woods; G Kitchingman; E Vanin; M Brenner Journal: Blood Date: 1998-09-15 Impact factor: 22.113
Authors: N K Cheung; B H Kushner; I Y Cheung; K Kramer; A Canete; W Gerald; M A Bonilla; R Finn; S J Yeh; S M Larson Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: A L Yu; M M Uttenreuther-Fischer; C S Huang; C C Tsui; S D Gillies; R A Reisfeld; F H Kung Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: Laurence J N Cooper; Max S Topp; Lisa Marie Serrano; Sergio Gonzalez; Wen-Chung Chang; Araceli Naranjo; Christine Wright; Leslie Popplewell; Andrew Raubitschek; Stephen J Forman; Michael C Jensen Journal: Blood Date: 2002-10-10 Impact factor: 22.113
Authors: Melinda S Merchant; Xuezhong Yang; Fraia Melchionda; Maria Romero; Ruth Klein; Carol J Thiele; Maria Tsokos; H Udo Kontny; Crystal L Mackall Journal: Cancer Res Date: 2004-11-15 Impact factor: 12.701
Authors: C Sampor; M D Guthmann; A Scursoni; W Cacciavillano; A Torbidoni; L Galluzzo; S Camarero; J Lopez; M T G de Dávila; L Fainboim; G L Chantada Journal: Front Oncol Date: 2012-12-20 Impact factor: 6.244
Authors: Sévérine de Bruijn; Sébastien Anguille; Joris Verlooy; Evelien L Smits; Viggo F van Tendeloo; Maxime de Laere; Koenraad Norga; Zwi N Berneman; Eva Lion Journal: Cancers (Basel) Date: 2019-09-19 Impact factor: 6.639